HCWB
NASDAQHCW Biologics Inc.
Price$1.23-3.08 (-71.46%)
2026-07-162026-10-16
News · 26 weeks66-12%
2026-04-192026-10-11
Mix2890d
- SEC Filings16(57%)
- Other8(29%)
- Insider3(11%)
- Dividends1(4%)
Latest news
25 items- SECSEC Form EFFECT filed by HCW Biologics Inc.EFFECT - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid TumorsCommunication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases
- SECSEC Form D filed by HCW Biologics Inc.D - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form S-1 filed by HCW Biologics Inc.S-1 - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form DEF 14A filed by HCW Biologics Inc.DEF 14A - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Announces Pricing of $1.5 Million Private PlacementMIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the "Offering") with an existing stockholder of the Company, (the "Investor"). Pursuant to a securities purchase agreement entered into on September 23, 2026 with the Investor (the "Purchase Agreement"), the Company agreed to issue and sell an aggregate of 903,614 units (the "Units"), with each Unit consisting of (i) one pre-funded warrant
- SECSEC Form PRER14A filed by HCW Biologics Inc.PRER14A - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T CellsAgreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for lowering the co
- SECSEC Form PRE 14A filed by HCW Biologics Inc.PRE 14A - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata TreatmentHCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patients diagnosed with alopecia areata show positive response after single dose of monotherapy at 3 micrograms/kg dose level MIRAMAR, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "
- SECSEC Form EFFECT filed by HCW Biologics Inc.EFFECT - HCW Biologics Inc. (0001828673) (Filer)
- SECAmendment: SEC Form S-1/A filed by HCW Biologics Inc.S-1/A - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased CellsHuman studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8+ T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and I
- SECSEC Form S-1 filed by HCW Biologics Inc.S-1 - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form 10-Q filed by HCW Biologics Inc.10-Q - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HCW Biologics Inc. (0001828673) (Filer)
- PRHCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial ResultsMIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026. On June 16, 2026, the Company announced its preliminary human data readout for the first two cohorts in a dose-escalating Phase 1 clinical study to evaluate HCW9302 as a monotherapy in patients with alopecia areata. HCW9302 is a fusion immunotherapeutic which is potentially a best-in-
- SECAmendment: SEC Form 10-Q/A filed by HCW Biologics Inc.10-Q/A - HCW Biologics Inc. (0001828673) (Filer)
- SECHCW Biologics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - HCW Biologics Inc. (0001828673) (Filer)
- SECSEC Form D filed by HCW Biologics Inc.D - HCW Biologics Inc. (0001828673) (Filer)
- INSIDERChief Executive Officer Wong Hing C bought $59,998 worth of shares (23,210 units at $2.58), increasing direct ownership by 23% to 125,845 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERSVP of Business Development Flowers Lee bought $19,998 worth of shares (7,736 units at $2.58), increasing direct ownership by 810% to 8,691 units (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
- INSIDERDirector Garrett Scott T bought $19,998 worth of shares (7,736 units at $2.58) (SEC Form 4)4 - HCW Biologics Inc. (0001828673) (Issuer)
HCWB FAQ
6 questionsWhere does HCWB stock trade?
HCW Biologics Inc. (HCWB) is listed on NASDAQ.What sector and industry is HCWB in?
HCW Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did HCW Biologics Inc. go public?
HCW Biologics Inc. (HCWB) completed its IPO in 2021.What are analysts saying about HCWB?
HCW Biologics Inc. has had 1 recent analyst action on file. The most recent action was from EF Hutton: Buy with a $1000.00 price target on 2021-11-19. Recent price targets cluster around $1000.00.What companies are similar to HCWB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HCWB side-by-side with any of them on Quantisnow.How can I track HCWB on Quantisnow?
Quantisnow aggregates HCW Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HCWB to receive live email and push alerts on every new disclosure.